← FDA DRUG APPROVALS

FDA ANDA · ANDA074226

GLIPIZIDE

Sponsor: AUROBINDO PHARMA USA

APPLICATION
ANDA074226
TYPE
ANDA
ORIGINAL APPROVAL
1994-05-10
LATEST ACTION
2017-04-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

GLIPIZIDEPrescription
GLIPIZIDE 10MG · TABLET · ORAL
GLIPIZIDEPrescription
GLIPIZIDE 5MG · TABLET · ORAL

Approval history

2017-04-11Labeling · Supplement 14 · standardAP
2017-04-11Labeling · Supplement 15 · standardAP
2013-07-26Labeling · Supplement 12 · standardAP
2009-05-19Labeling · Supplement 10AP
2001-09-25Labeling · Supplement 3AP
2000-03-24Labeling · Supplement 2AP
1998-02-05Manufacturing (CMC) · Supplement 1AP
1994-05-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →